Carlat Just Revived a 130-Year-Old Theory About Lithium — What PMHNPs in Private Practice Should Know About Allopurinol Augmentation

·

The Carlat Episode That Made Me Rethink Lithium

If you tuned into The Carlat Psychiatry Podcast on April 13, Chris Aiken and Kellie Newsome, PMHNP did something a little unusual. They spent an episode on lithium — but not the part you’ve heard a thousand times. They started in 1894, with a Danish psychiatrist named Frederik Lange, and ended in 2026 with a question every PMHNP in private practice should sit with for a minute: what if we’ve been thinking about lithium the wrong way?

The framing was that lithium’s story didn’t actually start with John Cade in 1949. It started decades earlier, with a half-right hypothesis that mood disorders were a disease of uric acid. The theory died, lithium got rediscovered for completely different reasons, and the uric acid angle quietly resurfaced in modern research — including five randomized trials of allopurinol added to mood stabilizers in mania. Aiken and Newsome’s question was essentially: should we be paying more attention to that?

It’s a fair question, and one with practical edges for anyone running a private psychiatric practice. Here is what the data actually says, what it means for prescribing, and how to think about it when the patient who needs it walks into your office on Monday.

Carlat Just Revived a 130-Year-Old Theory About Lithium — What PMHNPs in Private Practice Should Know About Allopurinol Augmentation

The 130-Year-Old Theory the Carlat Team Just Brought Back

Here is the historical thread, lightly compressed. In the late 1800s, the brothers Carl and Frederik Lange — both Danish psychiatrists — became convinced that recurrent depression and what we would now call bipolar disorder were caused by uric acid accumulation in the body. The “brain gout” theory was its day’s mainstream view. Carl Lange started using lithium for recurrent depression in 1886. Frederik followed in 1894, treating roughly 35 patients with melancholic and milder bipolar-spectrum depressions. The doses he reported are surprisingly close to what we use today.

The theory collapsed by the early 1900s. Lithium got shelved for half a century. John Cade rediscovered it for mania in 1949 — almost accidentally, while studying a different metabolite — and the rest became the textbook story.

What Aiken and Newsome highlighted is that the original theory was not entirely wrong. Modern research has shown that uric acid is in fact elevated during manic episodes. Lithium lowers it. And in the 2000s, NIMH-affiliated researchers revived the purinergic hypothesis of bipolar disorder seriously enough that it spawned a small but coherent body of randomized trials testing allopurinol — a gout medication that lowers uric acid — as an add-on for mania.

What the Allopurinol RCTs Actually Show

This is the part where most PMHNPs benefit from a clearer mental model than “interesting, but not standard of care.”

There are five placebo-controlled randomized trials worth knowing. Akhondzadeh and colleagues published the first in 2006: 41 inpatients on lithium plus haloperidol were randomized to allopurinol 300 mg per day or placebo for 8 weeks. The allopurinol arm beat placebo on the Young Mania Rating Scale. Machado-Vieira and colleagues followed in 2008 with a larger 180-patient trial of allopurinol 600 mg per day or dipyridamole versus placebo, all on top of lithium for four weeks. Allopurinol again came out ahead, with statistically significant YMRS reductions at days 21 and 28. A 2014 Weiser study did not show a significant difference, though baseline mania severity was lower in that sample.

The 2016 systematic review and meta-analysis in The British Journal of Psychiatry pooled the data and found a small-to-moderate effect size favoring allopurinol — standardized mean difference around minus 0.34 — with the strongest signal in the most severe presentations. A 2018 meta-analysis reached the same conclusion. The signal is real, modest, and most useful in severe acute mania where you are already stacking treatments.

What this is not: a replacement for lithium, valproate, or atypicals. What it is: a low-cost, well-tolerated, generic adjunct with a plausible mechanism and four of five positive trials. For perspective, that is a stronger evidence base than several augmentation strategies we use without thinking twice.

Why This Matters for the PMHNP in Private Practice

If you work inpatient, you may never reach for allopurinol — the hospital team will throw the standard arsenal at acute mania, and your job is to inherit a stable patient at discharge. But if you are a PMHNP running an outpatient private practice, the calculus is different. You see the patient who got admitted six weeks ago, came home on lithium plus quetiapine, and is now sliding back into a hypomanic spell. You see the patient with breakthrough manic symptoms despite “adequate” mood stabilization. You see the patient whose BMI, kidney function, and sedation tolerance limit how aggressively you can push the standard agents.

Carlat Just Revived a 130-Year-Old Theory About Lithium — What PMHNPs in Private Practice Should Know About Allopurinol Augmentation

That is where this evidence gets interesting. Allopurinol at 300 mg per day is cheap, well-tolerated for most people, and has a side-effect profile familiar to anyone who has prescribed it for gout. The serious risk — Stevens-Johnson syndrome, particularly in patients with HLA-B*5801, more common in patients of Han Chinese, Thai, and Korean ancestry — is real but rare and screenable. Drug interactions to watch include azathioprine and 6-mercaptopurine, which is uncommon in psychiatric populations but worth a quick chart check. Renal dosing matters in patients already on lithium where you are monitoring creatinine.

What you would document in your assessment: the patient meets criteria for breakthrough manic symptoms despite adequate trials of lithium and an atypical, you are considering an evidence-supported adjunct with a small-to-moderate effect size in the published literature, and you have discussed benefits, risks (including Stevens-Johnson rates), baseline labs (CBC, CMP, uric acid), and informed consent. That is a defensible note. The use is off-label in the FDA sense, like many things we do for treatment-resistant presentations, but the evidence base sits well within standard reasoning.

How I Would Think About It Clinically

I would narrow the candidate population pretty tightly. Allopurinol augmentation is not for the patient stabilizing nicely on lithium and an antipsychotic. It is for the patient with persistent or breakthrough manic symptoms despite reasonable trials, where you have already worked through dose optimization, adherence, substance use, and thyroid or sleep contributors. It is also not a substitute for getting someone to a higher level of care if their mania is genuinely escalating — outpatient practice has limits, and a manic patient with rising risk signals belongs in a different setting.

For the right patient, I would start at 300 mg per day, check uric acid and renal function before and a month in, and watch for rash like a hawk. Counsel the patient on what Stevens-Johnson looks like — any blistering, mucosal involvement, or fever with rash means stop the drug and head to an emergency department. Reassess at 4 to 8 weeks. If you are not seeing meaningful YMRS movement by then, the data does not support pushing further.

The Carlat Pattern PMHNPs in Private Practice Keep Running Into

What I have come to appreciate about Carlat — and the reason I keep flagging Carlat episodes when they drop — is that they consistently surface the augmentation strategies that are too small or too off-label for the big society guidelines but where the evidence is real and the cost is low. That is the exact zone where solo and small-group private practice has an edge over institutional care. We see patients longitudinally. We have time to try something thoughtful, monitor it, and either keep it or walk it back. We are not trapped in a 15-minute med check at a system that punishes outliers.

Carlat Just Revived a 130-Year-Old Theory About Lithium — What PMHNPs in Private Practice Should Know About Allopurinol Augmentation

Pramipexole for treatment-resistant depression. Anti-inflammatory augmentation with celecoxib for OCD. Allopurinol for breakthrough mania. These are not first-line moves. They are the moves you reach for when the standard playbook has not gotten the patient where they need to be, and you have the relationship and the time to manage them carefully. That is the practice we are in.

What to Actually Do This Week

If you found this useful and do not already subscribe to The Carlat Psychiatry Report, this is exactly the sort of issue that pays for itself in a single episode. Aiken and Newsome’s lithium piece is worth listening to twice — once for the history, once for the prescribing implications. The 2026 Medication Fact Book (8th edition) has updated lithium guidance and a new Bipolar Depression Treatment Algorithm worth reviewing. The Cambridge meta-analysis is open access and a 20-minute read. Pull up your three or four most complex bipolar charts and ask whether allopurinol augmentation might fit one of them.

And if you have been on the fence about whether to invest in a real psychopharmacology subscription as an independent PMHNP, this episode is the case for it. The clinical decisions you make in private practice are downstream of the quality of the inputs you read. Carlat is one of the few publications that gives PMHNPs a peer-level conversation about prescribing without pharmaceutical sponsorship coloring the conclusions.

Need help building your independent PMHNP private practice? Visit pmhnpwebsite.com for resources on starting, growing, and marketing your practice — written by and for psychiatric mental health nurse practitioners who run their own shops.